Literature DB >> 7893589

S-mephenytoin, sparteine and debrisoquine oxidation: genetic polymorphisms in a Turkish population.

N E Basci1, K Brosen, A Bozkurt, A Isimer, A Sayal, S O Kayaalp.   

Abstract

A mephenytoin test was carried out in 106 unrelated healthy Turkish volunteers. Racemic mephenytoin was coadministered with either debrisoquine or sparteine. The S/R mephenytoin ratio ranged from < 0.1 to 0.73 in 105 subjects, accordingly phenotyped as extensive metabolisers. One subject had an S/R mephenytoin ratio of 1.02, showing that he was a poor metaboliser of mephenytoin (0.94%, confidence interval 0.25% and 13.65%). In 48 subjects, the metabolic ratios of debrisoquine and sparteine were correlated significantly (rs = 0.61, P < 0.001).

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7893589      PMCID: PMC1364881          DOI: 10.1111/j.1365-2125.1994.tb04383.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  13 in total

1.  Correlations among the metabolic ratios of three test probes (metoprolol, debrisoquine and sparteine) for genetically determined oxidation polymorphism in a Japanese population.

Authors:  Y Horai; J Taga; T Ishizaki; K Ishikawa
Journal:  Br J Clin Pharmacol       Date:  1990-01       Impact factor: 4.335

2.  Dissociation of co-regulatory control of debrisoquin/phenformin and sparteine oxidation in Ghanaians.

Authors:  N M Woolhouse; M Eichelbaum; N S Oates; J R Idle; R L Smith
Journal:  Clin Pharmacol Ther       Date:  1985-05       Impact factor: 6.875

3.  Correlation between the metabolic ratios of debrisoquine and metoprolol in Turkish subjects.

Authors:  N E Basci; A Bozkurt; A Isimer; S O Kayaalp
Journal:  Pharmacol Toxicol       Date:  1994-07

4.  Polymorphic oxidation of sparteine and debrisoquine: related pharmacogenetic entities.

Authors:  M Eichelbaum; L Bertilsson; J Säwe; C Zekorn
Journal:  Clin Pharmacol Ther       Date:  1982-02       Impact factor: 6.875

5.  A family and population study of the genetic polymorphism of debrisoquine oxidation in a white British population.

Authors:  D A Evans; A Mahgoub; T P Sloan; J R Idle; R L Smith
Journal:  J Med Genet       Date:  1980-04       Impact factor: 6.318

6.  Hydroxylation polymorphisms of debrisoquine and mephenytoin in European populations.

Authors:  G Alván; P Bechtel; L Iselius; U Gundert-Remy
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

7.  The genetic control of sparteine and debrisoquine metabolism in man with new methods of analysing bimodal distributions.

Authors:  D A Evans; D Harmer; D Y Downham; E J Whibley; J R Idle; J Ritchie; R L Smith
Journal:  J Med Genet       Date:  1983-10       Impact factor: 6.318

8.  Sparteine oxidation polymorphism in Denmark.

Authors:  K Brøsen; S V Otton; L F Gram
Journal:  Acta Pharmacol Toxicol (Copenh)       Date:  1985-11

9.  Mephenytoin and sparteine oxidation: genetic polymorphisms in Denmark.

Authors:  A Drøhse; L Bathum; K Brøsen; L F Gram
Journal:  Br J Clin Pharmacol       Date:  1989-05       Impact factor: 4.335

10.  Sparteine metabolism in Canadian Caucasians.

Authors:  A Vinks; T Inaba; S V Otton; W Kalow
Journal:  Clin Pharmacol Ther       Date:  1982-01       Impact factor: 6.875

View more
  5 in total

1.  Omission of the deconjugation step in urine analysis and the unaltered outcome of CYP2D6 phenotyping with dextromethorphan.

Authors:  N E Basci; A Bozkurt; S O Kayaalp; A Sayal; A Isimer
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1998 Jan-Mar       Impact factor: 2.441

2.  Metabolic ratios of four probes of CYP2D6 in Turkish subjects: a cross-over study.

Authors:  A Bozkurt; N E Basçi; A Işimer; A Sayal; S O Kayaalp
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1996 Oct-Dec       Impact factor: 2.441

3.  Investigation of CYP2D6 Gene Polymorphisms in Turkish Population.

Authors:  Bayram Taskin; Ferda E Percin; Mehmet Ali Ergun
Journal:  Psychopharmacol Bull       Date:  2016-03-01

4.  CYP2C19 genotype does not represent a genetic predisposition in idiopathic systemic lupus erythematosus.

Authors:  S Kortunay; A Bozkurt; L Bathum; N E Basci; M Calgüneri; K Brøsen; S O Kayaalp
Journal:  Ann Rheum Dis       Date:  1999-03       Impact factor: 19.103

Review 5.  Clinical significance of the cytochrome P450 2C19 genetic polymorphism.

Authors:  Zeruesenay Desta; Xiaojiong Zhao; Jae-Gook Shin; David A Flockhart
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.